Format

Send to

Choose Destination
Sci Transl Med. 2016 Mar 30;8(332):332ra42. doi: 10.1126/scitranslmed.aaf1164.

Somatic PIK3CA mutations as a driver of sporadic venous malformations.

Author information

1
Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
2
Developmental Biology Program, Sloan Kettering Institute, New York, NY 10065, USA.
3
Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
4
Genomics Core Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
5
Department of Pathology, Hospital de la Santa Creu i Sant Pau, 167 Sant Antoni M. Claret, Barcelona 08025, Spain.
6
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
7
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona 08025, Spain.
8
Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. baselgaj@mskcc.org.

Abstract

Venous malformations (VM) are vascular malformations characterized by enlarged and distorted blood vessel channels. VM grow over time and cause substantial morbidity because of disfigurement, bleeding, and pain, representing a clinical challenge in the absence of effective treatments (Nguyenet al, 2014; Uebelhoeret al, 2012). Somatic mutations may act as drivers of these lesions, as suggested by the identification of TEK mutations in a proportion of VM (Limayeet al, 2009). We report that activating PIK3CA mutations gives rise to sporadic VM in mice, which closely resemble the histology of the human disease. Furthermore, we identified mutations in PIK3CA and related genes of the PI3K (phosphatidylinositol 3-kinase)/AKT pathway in about 30% of human VM that lack TEK alterations. PIK3CA mutations promote downstream signaling and proliferation in endothelial cells and impair normal vasculogenesis in embryonic development. We successfully treated VM in mouse models using pharmacological inhibitors of PI3Kα administered either systemically or topically. This study elucidates the etiology of a proportion of VM and proposes a therapeutic approach for this disease.

PMID:
27030594
PMCID:
PMC4962922
DOI:
10.1126/scitranslmed.aaf1164
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center